Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects

Drug Development and Industrial Pharmacy

Volumn 34, Issue 10, 2008, Pages 1090-1096

  Chono, Sumio ^a   Tanino, Tomoharu ^a   Seki, Toshinobu ^a   Morimoto, Kazuhiro ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Alveolar macrophages and lung epithelial lining fluid; Liposomal ciprofloxacin; PK PD; Pneumonia; Pulmonary administration

Indexed keywords

CIPROFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; LEGIONELLA PNEUMOPHILA; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PNEUMONIA; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; CIPROFLOXACIN; EPITHELIUM; LIPOSOMES; LUNG; MACROPHAGES, ALVEOLAR; MALE; PNEUMONIA, BACTERIAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 52949135181     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040801958421     Document Type: Article

References (45)

1. Alba-Loureiro, T. C., Martins, E. F., Landgraf, R. G., Jancar, S., Curi, R., & Sannomiya, P. (2006). Role of insulin on PGE2 generation during LPS-induced lung inflammation in rats. Life Sci., 78, 578-585.
2. Andes, D., & Craig, W. A. (2003). Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob. Agents Chemother., 47, 3935-3941.
3. Antonini, J. M., & Reasor, M. J. (1991). Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture. Biochem. Pharmacol., 42, S151-S156.
4. Blaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother., 31, 1054-1060.
5. Blau, H., Klein, K., Shalit, I., Halperin, D., & Fabian, I. (2007). Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line. Am. J. Physiol. Lung Cell Mol. Physiol., 292, L343-L352.
6. Branford, M. M. (1976). A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
7. Chono, S, Tanino, T, Seki, T, & Morimoto, K. (2006). Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J. Drug Target., 14, 557-566.
8. Chono, S, Tanino, T, Seki, T, & Morimoto, K. (2007). Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections. Drug Metab. Pharmacokinet., 22, 88-95.
9. Chono, S, Tanino, T, Seki, T, & Morimoto, K. (2008) Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release, 127, 50-58.
10. Craig, W. A. (1995). Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis., 22, 89-96.
11. Dalhoff, A., & Shalit, I. (2003). Immunomodulatory effects of quinolones. Lancet Infect. Dis., 3, 359-371.
12. Densen, P., & Mandell, G. L. (1980). Phagocyte strategy vs. microbial tactics. Rev. Infect. Dis., 2, 817-838.
13. Ferrari, G., Langen, H., Naito, M., & Pieters, J. (1999). A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell, 14, 435-447.
14. Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother., 37, 1073-1081.
15. Greub, G., & Raoult, D. (2004). Microorganisms resistant to free-living amoebae. Clin. Microbiol. Rev., 17, 413-433.
16. Harb, O. S., Gao, L. Y., & Abu Kwaik, Y. (2000). From protozoa to mammalian cells: a new paradigm in the life cycle of intracellular bacterial pathogens. Environ. Microbiol., 2, 251-265.
17. Harnett, S. J., Fraise, A. P., Andrews, J. M., Jevons, G., Brenwald, N. P., & Wise, R. (2004). Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J. Antimicrob. Chemother., 53, 783-792.
18. Horwitz, M. A., & Silverstein, S. C. (1980). Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J. Clin. Invest., 65, 82-94.
19. Hyatt, J. M., McKinnon, P. S., Zimmer, G. S., & Schentag, J. J. (1995). The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet., 28, 143-160.
20. Ikaheimo, I., Syrjala, H., Karhukorpi, J., Schildt, R., & Koskela, M. (2000). In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J. Antimicrob. Chemother., 46, 287-290.
21. Ishida, T., Hashimoto, T., Arita, M., Ito, I., & Osawa, M. (1998). Etiology of community-acquired pneumonia in hospitalized patients: A 3-year prospective study in Japan. Chest, 114, 1588-1593.
22. Kohno, Y., Yoshida, H., Suwa, T., & Suga, T. (1990). Uptake of clarithromycin by rat lung cells. J. Antimicrob. Chemother., 26, 503-513.
23. Krieg, D. P., Helmke, R. J., German, V. F., & Mangos, J. A. (1988). Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro. Infect. Immun., 56, 3173-3179.
24. McKinney, J. D., Honer, zu Bentrup, K., Munoz-Elias, E. J., Miczak, A., Chen, B., Chan, W. T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., Jr., & Russell, D. G. (2000). Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature, 406, 735-738.
25. Miyashita, N., Niki, Y., Kishimoto, T., Nakajima, M., & Matsushima, T. (1997). In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob. Agents Chemother., 41, 1331-1334.
26. Mohr, J. F., McKinnon, P. S., Peymann, P. J., Kenton, I., Septimus, E., & Okhuysen, P. C. (2005). A restrospextive, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Phamacotherapy, 25, 1303-1309.
27. Moore, R. D., Lietman, P. S., & Smith, C. R. (2005). Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis., 155, 93-99.
28. Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2002). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents., 19, 355-358.
29. Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother., 55, 601-607.
30. Neu, H. C., Fang, W., Gu, J. W., & Chin, N. X. (1992). In vitro activity of OPC-17116. Antimicrob. Agents Chemother., 36, 1310-1305.
31. Onodera, Y., Tanaka, M., & Sato, K. (2001). Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. J. Antimicrob. Chemother., 47, 447-450.
32. Otani, T., Tanaka, M., Ito, E., Kurosaka, Y., Murakami, Y., Onodera, K., Akasaka, T., & Sato, K. (2003). In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone. Antimicrob. Agents Chemother., 47, 3750-3759.
33. Otsu, Y., Yanagihara, K., Fukuda, Y., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Kadota, J., Tashiro, T., Murata, I., & Kohno, S. (2003). In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model. Antimicrob. Agents Chemother., 47, 3699-3703.
34. Pan, X. S., & Fisher, L. M. (1997). Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother., 41, 471-474.
35. Patmore, L., Fraser, S., Mair, D., & Templeton, A. (2000). Effect of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. Eur. J. Pharmacol., 406, 449-452.
36. Peterson, P. K., Verhoef, J., Sabath, L. D., & Quie, P. G. (1977). Effect of protein A on staphylococcal opsonization. Infect. Immun., 15, 760-764.
37. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornseif, B., Reichl, V., Natarajan, J., & Corrado, M. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA., 279, 125-129.
38. Rennard, S. I., Basset, G., Lecossier, D., O'Donnell, K. M., Pinkston, P., Martin, P. G., & Crystal, R. G. (1986). Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol., 60, 532-538.
39. Safdar, A., & Armstrong, D. (2003). Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997). J. Clin. Microbiol., 41, 483-485.
40. Smith, H. J., Nichol, K. A., Hoban, D. J., & Zhanel, G. G. (2003). Stretching the mutant prevention concentration (MPC) beyond its limits. J. Antimicrob. Chemother., 51, 1323-1325.
41. Stiver, H. G., Zachidniak, K., & Speert, D. P. (1988). Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin. Invest. Med., 11, 247-252.
42. Takahata, M., Mitsuyama, J., Yamashiro, Y., Yonezawa, M., Araki, H., Todo, Y., Minami, S., Watanabe, Y., & Narita, H. (1999). In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob. Agents Chemother., 43, 1077-1084.
43. Tattevin, P., Messiaen, T., Pras, V., Ronco, P., & Biour, M. (1998). Confusion and general seizures following ciprofloxacin administration. Nephrol. Dial. Transplant., 13, 2712-2713.
44. Toutain, P. L., del Castillo, J. R., & Bousquet-Melou, A. (2002). The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res. Vet. Sci., 73, 105-114.
45. World Health Organization. (2003). The world health report 2003 - shaping the future, from http://www.who.int/whr/2003/en/